Your browser doesn't support javascript.
loading
Treating COVID-19: Evolving approaches to evidence in a pandemic.
Lee, Cheryl K; Merriam, Louis T; Pearson, Jeffrey C; Lipnick, Michael S; McKleroy, William; Kim, Edy Y.
Affiliation
  • Lee CK; Division of Hospital Medicine, Department of Medicine, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Merriam LT; Division of Hospital-Based Medicine, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Pearson JC; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Lipnick MS; Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
  • McKleroy W; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA.
  • Kim EY; Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Cell Rep Med ; 3(3): 100533, 2022 03 15.
Article in En | MEDLINE | ID: mdl-35474746
The rapid pace of the COVID-19 pandemic precluded traditional approaches to evaluating clinical research and guidelines. We highlight notable successes and pitfalls of clinicians' new approaches to managing evidence amidst an unprecedented crisis. In "Era 1" (early 2020), clinicians relied on anecdote and social media, which democratized conversations on guidelines, but also led clinicians astray. "Era 2" (approximately late 2020 to early 2021) saw preprints that accelerated new interventions but suffered from a surfeit of poor-quality data. In the current era, clinicians consolidate the evidentiary gains of Era 2 with living, online clinical guidelines, but the public suffers from misinformation. The COVID-19 pandemic is a laboratory on how clinicians adapt to an absence of clinical guidance amidst an informational and healthcare crisis. Challenges remain as we integrate new approaches to innovations made in the traditional guideline process to confront both the long tail of COVID-19 and future pandemics.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Social Media / COVID-19 Type of study: Guideline Limits: Humans Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Social Media / COVID-19 Type of study: Guideline Limits: Humans Language: En Journal: Cell Rep Med Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States